Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) are crucial for chronic myelogenous leukemia (CML) treatment.
• Resistance to TKIs, particularly imatinib, remains a significant clinical challenge in CML management.
• BCR-ABL mutations are a primary cause of imatinib resistance, leading to the development of next-generation TKIs.

Purpose of the Study:

• To explore the multifaceted mechanisms of TKI resistance in CML beyond BCR-ABL mutations.
• To highlight the need for a comprehensive understanding of resistance pathways to guide future therapeutic strategies.
• To emphasize the potential of combination therapies for overcoming treatment failure.

Main Methods:

• Review of existing literature on TKI resistance in CML.
• Analysis of identified mechanisms contributing to treatment failure.
• Classification of TKIs based on their activity against BCR-ABL mutations.

Main Results:

• BCR-ABL mutations account for approximately 50% of TKI treatment failures in CML.
• Alternative resistance mechanisms involve continued BCR-ABL dependency or BCR-ABL-independent oncogenic signaling.
• Second-generation (nilotinib, dasatinib, bosutinib) and third-generation (ponatinib) TKIs target various BCR-ABL mutations.

Conclusions:

• Understanding diverse resistance mechanisms is essential for overcoming clinical resistance in CML.
• Tailored combination therapies involving targeted inhibitors hold promise for future CML treatment.
• Further research into non-BCR-ABL-mediated resistance is critical for improving patient outcomes.